CD7+ Cell Targeted Antibody-Conjugated Premade CD19 CAR mRNA Lipid Nanoparticle
 
The CD7+ Cell Targeted Antibody-Conjugated Premade CD19 CAR mRNA Lipid Nanoparticle is a targeted delivery system designed for precise mRNA delivery to CD7+ cells. The formulation combines the specificity of an anti-human CD7 antibody with lipid nanoparticle delivery to achieve cellular targeting. CD7 is expressed on T cells and NK cells, making it a route to in vivo engineering of the effector populations used in CAR-T and CAR-NK research. The system features covalently conjugated CD7 antibodies on the surface of SM102-based lipid nanoparticles, loaded with fully modified CD19 CAR mRNA containing N1-methyl-pseudouridine (m1Ψ) modifications for improved stability and reduced immunogenicity.
 
Key Features
Targeted Delivery: Surface-conjugated anti-human CD7 mAb for specific targeting of CD7+ cells
Transient CAR Expression: Anti-CD19 CAR mRNA drives non-integrating CAR expression in immune effector cells
Enhanced mRNA Stability: CD19 CAR mRNA with 100% U-base modification using N1-methyl-pseudouridine (m1Ψ) and a Cap1 structure
Optimized Formulation: SM102-based ionizable lipid system for improved cellular uptake and endosomal escape
Covalent Conjugation: Antibody covalently linked to lipid molecules ensuring stable targeting functionality
Ready-to-Use: Premade formulation eliminates preparation time and ensures batch-to-batch consistency
Research-Grade Quality: Manufactured under controlled conditions for reliable experimental results
 
Applications
In Vivo CAR Generation: Evaluating direct engineering of CAR-T and CAR-NK cells without ex vivo manufacturing
B-Cell Malignancy Models: Studying CD19-directed approaches in acute lymphoblastic leukemia and non-Hodgkin lymphoma models
Targeted Delivery Research: Comparing antibody-conjugated tLNP targeting against untargeted LNP controls
Immunotherapy Development: Screening targeted delivery approaches for T cell- and NK cell-based therapies
Proof-of-Concept Studies: Demonstrating targeted mRNA delivery efficiency to specific immune cell populations
Flow Cytometry Analysis: Quantitative assessment of targeting efficiency and CAR surface expression
 
Product Specifications
Parameter
Specification
Payload
CD19 CAR mRNA (m1Ψ, Cap1)
Payload mRNA Length
1789 nt
Conjugated Antibody
CD7 mAb
Ionizable Lipid
SM102
Formulation Components
Ionizable lipid, DSPC, PEG-2000 DMG, Cholesterol
Storage Buffer
10% Sucrose in TBS
Appearance
Clear and colorless
Concentration
Batch specific (~0.1 mg/mL)
Availability
On-demand
 
Storage & Handling Instructions
Storage Temperature: Store at 4°C immediately upon receipt
Shipping: Product is shipped on ice packs to maintain cold chain integrity
Handling Precautions:
Avoid freeze-thaw cycles to maintain nanoparticle integrity
Handle gently to prevent aggregation
Use sterile technique when aliquoting or diluting
Protect from prolonged exposure to room temperature
Keep away from light to preserve mRNA stability
Stability: When stored properly at 4°C, the product maintains stability for 6 months from the date of manufacture. For optimal performance, use within the specified timeframe.
 
Custom Solutions
At PreciGenome, we understand that research requirements vary. We offer comprehensive customization options for this product:
Alternative Targeting Antibodies: Custom antibody conjugation for different cell surface markers
Payload Modifications: Alternative mRNA sequences, reporters, or therapeutic genes
Formulation Adjustments: Modified lipid compositions or concentrations
Scale Options: Various volume and concentration specifications
Buffer Systems: Alternative storage and working buffers
Bulk Manufacturing: Large-scale production for extensive studies
Our technical team works closely with researchers to develop tailored solutions that meet specific experimental needs and research objectives.
 
Important Notes
For Research Use Only. This product is not for human or veterinary use.
For technical support, custom formulations, or bulk orders, please contact us.
This product contains genetically modified materials and should be handled according to institutional biosafety guidelines
Performance may vary depending on cell type, experimental conditions, and handling procedures
Optimal transfection conditions should be determined empirically for each specific application
Product specifications are subject to batch-specific variations; refer to individual Certificate of Analysis
Users should validate targeting efficiency and expression levels in their specific experimental systems